Nucleoside reverse transcriptase inhibitors (NRTIs) are the backbone of highly active antiretroviral therapy (HAART) regimens recommended for the treatment of patients with HIV infection (Dybul et al., 2002 ; Panel on Clinical Practices for Treatment of HIV Infection, 2003) . HAART regimens have substantially reduced morbidity and mortality associated with HIV disease (Palella et al., 1998; Murphy et al., 2001) . However, resistance to antiretrovirals, including NRTIs, is increasingly common and is an important cause of virological treatment failure (Deeks, 2004) . A longitudinal study in France found that 78% of HIV samples collected from treated patients between 1997 and 2000 had mutations in the reverse transcriptase (RT) genome conferring resistance to at least one NRTI . A quarter of isolates were genotypically resistant to all three major antiretroviral classes, that is NRTIs, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. Similar data have been reported from the United States (Kagan et al., 2000; Richman et al., 2004) . Primary infection with NRTI-resistant HIV is also of increasing concern in some countries, including the United States (Salomon et al., 2000; UK Collaborative Group, 2001; Little et al., 2002) . 
Introduction
NRTIs share a common mechanism of action: following intracellular activation to the triphosphate (TP) form, they compete with endogenous phosphonated nucleotides for binding to viral RT. RT incorporates NRTI-monophosphates into nascent DNA chains during replication, causing chain termination. Resistance to NRTIs occurs primarily via two mechanisms: increased rates of phosphorylysis of the incorporated NRTI-monophosphate and improved specificity of the RT for the natural nucleoside triphosphate relative to the triphosphorylated NRTI (de Mendoza et al., 2002) . Mutations at codons 41, 67, 70, 210, 215 and 219 of the RT genome -collectively known as 'thymidine analogue mutations' (TAMs) because of their initial association with resistance to zidovudine and stavudine -act to increase the rate of phosphorylysis. HIV-1 acquires these mutations sequentially during NRTI treatment, and the accumulation of these mutations leads to progressive decreases in susceptibility to all NRTIs (Whitcomb et al., 2003) . This accumulation occurs via two pathways determined by the first TAM present at first treatment failure, which is itself determined by the treatment regimen. One pathway originates through mutations at codons 41 or 215 (predominantly 215Y ). After both of these mutations have been selected, mutations at codons 210, 67 and 219 are accumulated sequentially. The other pathway is characterized by the accumulation of three mutations at codons 67, 70 and 219. Once these three mutations have been selected, mutations at codons 215 (predominantly 215F) and 41 are accumulated sequentially (Flandre et al., 2003 , Marcelin et al., 2004 .
Other mutations, such as the M184V mutation, alter the structure of the NRTI binding site upon RT. Such mutations result in better discrimination between the nucleoside triphosphate substrate and the NRTI-triphosphate, diminishing the probability of a chain termination event during reverse transcription. M184V is rapidly selected during lamivudine-containing HAART (Descamps et al., 2000; Maguire et al., 2000) and causes high-level resistance to lamivudine and reduced susceptibilty to didanosine, zalcitabine and abacavir (Whitcomb et al., 2003) . Because of the large number of patients who received sequential monotherapy or dual NRTI therapy with zidovudine or stavudine and lamivudine prior to the introduction of triple drug combination therapy, and the large numbers of patients who take lamivudine with zidovudine or stavudine in HAART regimens, many treatment-experienced patients harbour viruses that contain both TAMs and the M184V mutation.
SPD754 (also known as AVX-754, and formerly as BCH-10618) is a novel deoxycytidine analogue NRTI in clinical development. SPD754 is the (-)-enantiomer of 2′-deoxy-3′-oxa-4′-thiocytidine (dOTC or BCH-10652) (de Muys et al., 1999; Taylor et al., 2000) . SPD754 showed good antiviral activity against HIV-1 isolates in vitro, both alone and in combination with other NRTIs (De Muys et al., 1999; Taylor et al., 2000) , good antiviral activity against viruses with a range of NRTI-resistant genotypes (De Muys et al., 1999; Taylor et al., 2000) , and a low potential for cellular and mitochondrial toxicity (Bethell RC 
Materials and methods

Compounds
SPD754 was synthesized at Shire Pharmaceuticals (Laval, Quebec, Canada) as described previously (Mansour et al., 1995) . Zidovudine and didanosine were sourced from Sigma Chemical (MO, USA), lamivudine from Roxanne Labs (CT, USA), abacavir from GlaxoSmithKline (NC, USA) and tenofovir from Gilead Sciences (CA, USA). The structures of all the antiviral compounds used in the present study are shown in Figure 1 .
Viruses and cells
Studies were performed using a panel of HIV-1 strains with specific TAM patterns based on the data on pathways for the selection of TAMs from the studies of Marcelin et al. (2004) and Flandre et al. (2003) . TAMs were defined as M41L, D67N, K70R, L210W, T215F or Y, and K219E, H, N, Q, R. Panels of clinical HIV-1 isolates with these genotypic patterns were then selected from the ViroLogic library of genotyped clinical isolates. Ten to twenty samples with each genotype were selected.
Mutations at codons 44 (E44A or D) and 118 were allowed within groups. Samples with mixtures at codons 41, 67, 70, 184, 210, 215 and 219 were excluded. Viruses containing insertions at codon 69 or the Q151M mutation were excluded, as were those with other mutations not typically included among TAMs (for example K65R, L74I or V, and V75A, M, S, or T). Repeat samples from the same patient with different genotypes were included, but only one isolate from any given patient within any genotypic group was permitted. None of the viruses contained mutations known to confer resistance to either non-nucleoside reverse transcriptase inhibitors or protease inhibitors.
The effect of the M184V mutation on the antiviral activity of NRTIs was determined by constructing similar panels of viruses. Six such panels measured the effect of the presence of the M814V mutation on the NRTI sensitivity of wild-type virus and viruses with mutations TAMs at codons 41 and 215, or codons 67, 70 and 219.
In all tests, NRTI susceptibility in the clinical isolates was compared with that of a reference virus (strain CNDO) containing the RT (and protease) sequences of the NL4-3 HIV-1. Cells were cultured as previously described for the automated PhenoSense HIV assay (Petropoulos et al., 2000) .
Antiviral assay
Phenotypic viral susceptibility to the aforementioned NRTIs was assessed using the PhenoSense HIV assay (Petropoulos et al. 2000) . The results were expressed as median fold-change in 50% inhibitory concentration (IC 50 ) in clinical isolates, as compared with the reference strain.
Statistical methods
Analysis of the effect of M184V mutation on viral susceptibility to NRTIs was performed using pair-wise comparisons and plotted as bivariate scattergrams with linear regression lines for the whole dataset or for the groups with or without M184V. Pair-wise regression analysis of log-transformed median fold-changes in susceptibility was undertaken to evaluate the level of cross resistance between SPD754 and the other NRTIs tested.
Results
A total of 215 isolates were selected (Table 1) . These isolates exhibited eight genotypic patterns containing only TAMs, four in each of the two TAM pathways. Consistent with previous results (Marcelin et al., 2004) , viruses in the 41, 215 pathway contained predominantly Y at codon 215, whereas viruses in the 67, 70, 219 pathway contained predominantly F. A further three panels contained viruses with M184V together with mutations with no TAMs or 
Effect of TAMs on the antiviral activity of SPD754 and other NRTIs
Viruses with no NAMs had a median 0.9-fold change in susceptibility to SPD754 (range 0.7-1.1) relative to the reference strain. The median fold-changes for all the other NRTIs against this panel of viruses were also close to 1.0. Mutations at codons 41 and 215 conferred a median 33-fold change in susceptibility to zidovudine relative to wild-type HIV-1. The sequential addition of mutations at codons 210, 67 and 219 progressively reduced susceptibility to zidovudine until a median 438-fold reduction was observed in the presence of all five mutations (Table 1) . Mutations at codons 67 and 70 conferred a median 5.0-fold change in susceptibility to zidovudine. A progressive decrease in susceptibility occurred with the accumulation of further mutations at codons 210, 67 and 219 until a median 108-fold reduction occurred in the presence of all five mutations (Table 1) . In contrast, mutations at codons 41 and 215 produced a limited 1.2-fold (range 0.7-1.7) reduction in susceptibility to SPD754. The incremental effects of further TAMs in this pathway reached a 1.8-fold reduction (range 1.2-2.6) when all five were present (Table 1) . Similar fold-changes in susceptibility to didanosine were observed, while reductions in susceptibility to lamivudine, abacavir and tenofovir in the presence of all five TAMs were 4.8 (range 2.2-7.6), 4.5 (range 1.8-6.7) and 3.6 (range 1.1-9.1), respectively. These levels of resistance to didanosine, abacavir and tenofovir and lamivudine are consistent with the results of a previous study (Whitcomb et al. 2003) .
Mutations at codons 67 and 70 had no effect on susceptibility to SPD754 (median fold-change 1.0; range 0.8-1.2). Accumulation of additional TAMs within this pathway resulted in minimal changes in SPD754 susceptibility, which reached 1.3-fold change (0.9-1.9) when all five TAMs were present (Table 1) . Again, similar changes in viral susceptibility to didanosine were observed, while fold reductions in susceptibility to lamivudine, abacavir and tenofovir in the presence of all five TAMs were 3.2 (range 1.7-5.1), 3.0 (range 1.5-5.3) and 2.5 (range 1.5-5.0), respectively.
Effect of M184V mutation on the antiviral activity of SPD754 and other NRTIs Susceptibility to NRTIs was assessed in the presence and absence of the M184V mutation in wild-type HIV-1 and isolates with mutations at codons 41 and 215, or 67, 70 and 219. As expected, the presence of the M184V mutation reduced median viral susceptibility to lamivudine to such a large extent that the IC 50 value could not be determined on any virus containing this mutation, regardless of the background genotype.
Pair-wise comparisons showed that M184V addition was associated with an approximate 1.8-fold reduction in susceptibility to SPD754 in all genotypes (Table 1) . In comparison, M184V reduced abacavir susceptibility 2.1 to 3.1-fold and didanosine susceptibility by 1.3 to 1.5-fold. M184V slightly increased viral susceptibility to tenofovir, and this effect appeared slightly greater in the groups of viruses containing TAMs than in the group lacking TAMs (2.1 and 2.3-fold increased susceptibility in the 67, 70, 219 and 41, 215 groups respectively, compared with 1.5-fold in the viruses lacking TAMs).
Cross resistance between NRTIs
Pair-wise regression analyses for SPD754 indicated that, as for all other NRTIs (Whitcomb et al., 2003) , there is significant cross resistance between SPD754 and the other NRTIs tested (r 2 approximately 0.5-0.75) as shown in Figure 2 . The extent of cross resistance with zidovudine and tenofovir was only apparent when samples with or without M184V were analysed separately, whereas correlations between SPD754 and abacavir or didanosine were evident with or without splitting the samples by the presence of M184V. However, in both subgroups, the extent of cross resistance was substantial. In addition, there was significant cross resistance between SPD754 and lamivudine in samples lacking M184V (r 2 =0.70; data not shown).
Discussion
Previous studies have demonstrated that TAM accumulation progressively decreases HIV susceptibility to all NRTIs (Whitcomb et al., 2003) . While measurable in vitro resistance does not always result in reduced clinical susceptibility, clinical 'cut off ' thresholds for resistance assigned for various NRTIs indicate that clinically significant reductions in susceptibility to a number of NRTIs can occur in isolates with sufficient numbers of TAMs (Whitcomb et al., 2003) .
Data from the present study confirm that TAMs incrementally increase resistance to all of the NRTIs tested in the present study, namely zidovudine, lamivudine, abacavir, didanosine, tenofovir and SPD754. SPD754, along with didanosine, showed a decrease in susceptibility of <50% in the presence of up to five TAMs. The presence of five mutations at codons 41, 67, 210, 215 , and 219 conferred a median 1.8-fold reduction in susceptibility to SPD754. Similarly the presence of TAMs at codons 41, 67, 70, 215 and 219 conferred a median 1.3-fold reduction in susceptibility to SPD754. Until studies are performed to determine the clinically relevant threshold for SPD754, we cannot determine whether or not these modest reductions in susceptibility will impact virological response rates. Nonetheless, the relatively low magnitude of the susceptibility reductions suggest that SPD754 will be useful in the treatment of NRTI-experienced HIV-infected patients, in whom cross resistance among NRTIs limits the available options for salvage therapy (Deeks, 2004) .
The structural basis of the very high level of resistance to lamivudine conferred by the M184V and M184I mutations has been attributed to steric interactions between the branched side-chain of these amino acids and thiomethylene group of lamivudine, which is very much larger than the oxygen atom of the natural substrates of the reverse transcriptase (Sarafianos et al., 1999) . The very much lower magnitude of the decrease in susceptibility to SPD754 conferred by M184V is therefore likely to result from the much smaller size of a single sulphur atom of SPD754 when compared to the corresponding thiomethylene group of lamivudine, as is shown in Figure 1 . Whitcomb et al. (2003) have proposed that NRTIs can be divided into two groups according to the effect of the M184V mutation in vitro: susceptibility to 'Group 1' agents (zidovudine, stavudine, tenofovir and adefovir) is increased by M184V, while susceptibility to Group 2 agents (lamivudine, emtricitabine, didanosine, zalcitabine and abacavir) is decreased (Whitcomb et al., 2003) . The clinical relevance of these in vitro observations will vary according to the clinical cut off for individual agents. The effect of the M184V mutation on SPD754 susceptibility was consistent regardless of the background genotype: the mutation produced a small (1.8-fold) decrease in susceptibility to SPD754 in the presence of TAMs accumulated via either pathway. Clearly, SPD754 belongs in the second category of NRTIs, although its activity was affected less than that of many other members. In common with previous reports (Miller et al., 2003) , M184V slightly increased viral susceptibility to tenofovir in the present study. M184V-positive HIV-1 mutants show reduced replicative fitness owing to enhanced fidelity and/or impaired processivity in the RT enzyme (Back et al., 1996; Naeger et al., 2001; Diallo et al., 2003) . Furthermore, there was a 0.5 log 10 reduction in viral load relative to baseline viral load among patients who received lamivudine monotherapy and in whom the M184V was rapidly selected (Kuritzkes et al. 1996) . These observations have led some to propose that lamivudine administration should be continued in patients with the M184V mutation in order to maintain a reduced replicative capacity. However, an NRTI with potent clinical antiretroviral activity [Bethell RC & Collins P (2004) Genotypic and phenotypic analysis of HIV-1 isolates from patients after 10 days monotherapy with SPD754. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA. 30 October-2 November, 2004. Abstract H-206] and demonstrated virological activity against M184V-containing isolates, such as SPD754, is likely to offer greater clinical benefit than can be achieved by maintenance of a virus with reduced fitness. Future studies will determine whether SPD754 maintains the M184V mutation during therapy.
In conclusion, SPD754 is likely to show activity against HIV-1 containing multiple TAMs, in the absence or presence of the M184V mutation. These data suggest that SPD754 is a promising new NRTI for the treatment of NRTI-experienced HIV-infected patients, and support its investigation for this indication in large-scale clinical trials.
